Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Marcelo Rocha Cruz"'
Autor:
Luigi Formisano, Yao Lu, Alberto Servetto, Ariella B. Hanker, Valerie M. Jansen, Joshua A. Bauer, Dhivya R. Sudhan, Angel L. Guerrero-Zotano, Sarah Croessmann, Yan Guo, Paula Gonzalez Ericsson, Kyung-min Lee, Mellissa J. Nixon, Luis J. Schwarz, Melinda E. Sanders, Teresa C. Dugger, Marcelo Rocha Cruz, Amir Behdad, Massimo Cristofanilli, Aditya Bardia, Joyce O’Shaughnessy, Rebecca J. Nagy, Richard B. Lanman, Nadia Solovieff, Wei He, Michelle Miller, Fei Su, Yu Shyr, Ingrid A. Mayer, Justin M. Balko, Carlos L. Arteaga
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Era+ breast cancer patients often develop resistance to endocrine therapy. Here, the authors show that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK4/6, and anti-est
Externí odkaz:
https://doaj.org/article/c9a8bb9c2aac44dba476758c76c4a8d4
Autor:
Orlando Jorge Martins TORRES, Márcio Carmona MARQUES, Fabio Nasser SANTOS, Igor Correia de FARIAS, Anelisa Kruschewsky COUTINHO, Cássio Virgílio Cavalcante de OLIVEIRA, Antonio Nocchi KALIL, Celso Abdon Lopes de MELLO, Jaime Arthur Pirola KRUGER, Gustavo dos Santos FERNANDES, Claudemiro QUIREZE JR, André M. MURAD, Milton José de BARROS E SILVA, Charles Edouard ZURSTRASSEN, Helano Carioca FREITAS, Marcelo Rocha CRUZ, Rui WESCHENFELDER, Marcelo Moura LINHARES, Leonaldson dos Santos CASTRO, Charles VOLLMER, Elijah DIXON, Héber Salvador de Castro RIBEIRO, Felipe José Fernandez COIMBRA
Publikováno v:
ABCD: Arquivos Brasileiros de Cirurgia Digestiva, Vol 29, Iss 3, Pp 173-179 (2016)
ABSTRACT In the last module of this consensus, controversial topics were discussed. Management of the disease after progression during first line chemotherapy was the first discussion. Next, the benefits of liver resection in the presence of extra-he
Externí odkaz:
https://doaj.org/article/d65d513c372c4c649d76749865c995d4
Autor:
Rubens Barros Costa, Ricardo Costa, Jason Kaplan, Marcelo Rocha Cruz, Hiral Shah, Maria Matsangou, Benedito Carneiro
Publikováno v:
Case Reports in Oncological Medicine, Vol 2017 (2017)
Glioblastoma multiforme is the most common malignant primary central nervous system neoplasm in adults. It has a very aggressive natural history with a median overall survival estimated at 14.6 months despite multimodality treatment. Extracranial met
Externí odkaz:
https://doaj.org/article/bd63ee0a18ba452896001efc7e98a903
Autor:
Valerie M. Jansen, Yao Lu, Paula Gonzalez Ericsson, Wei He, Luis J. Schwarz, Richard B. Lanman, Dhivya R. Sudhan, Yu Shyr, Teresa C. Dugger, Yan Guo, Carlos L. Arteaga, Marcelo Rocha Cruz, Alberto Servetto, Ingrid A. Mayer, Amir Behdad, Aditya Bardia, Luigi Formisano, Sarah Croessmann, Nadia Solovieff, Angel Guerrero-Zotano, Fei Su, Michelle Miller, Justin M. Balko, Mellissa J. Nixon, Joyce O'Shaughnessy, Ariella B. Hanker, Kyungmin Lee, Melinda E. Sanders, Massimo Cristofanilli, Joshua A. Bauer, Rebecca J. Nagy
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-14 (2019)
Nature Communications
Nature Communications
Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resista
Autor:
Ricardo Costa, Fabio Tavora, Benedito A. Carneiro, Young Kwang Chae, Sarah Chuzi, Marcelo Rocha Cruz, Francis J. Giles
Publikováno v:
Cancer Management and Research
Repositório Institucional da Universidade Federal do Ceará (UFC)
Universidade Federal do Ceará (UFC)
instacron:UFC
Repositório Institucional da Universidade Federal do Ceará (UFC)
Universidade Federal do Ceará (UFC)
instacron:UFC
Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint i
Autor:
Cesar A. Santa-Maria, Francis J. Giles, William J. Gradishar, Ricardo Costa, Benedito A. Carneiro, Massimo Cristofanilli, Young Kwang Chae, Devalingam Mahalingam, Ami N. Shah, Marcelo Rocha Cruz
Publikováno v:
Cancer Treatment Reviews. 53:111-119
Triple negative breast cancer (TNBC) accounts for 10–20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that
Autor:
Marcelo Rocha Cruz, Antonio C. Buzaid
Publikováno v:
Breast Diseases ISBN: 9783030136352
Predictive factors are responsible in determining the recurrence risk and death related to cancer and therefore to stablish the natural history of the disease regardless the treatment performed. Predictive factors are those that determine the outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecc27a20b074b1ccecbcf09afe6dba60
https://doi.org/10.1007/978-3-030-13636-9_29
https://doi.org/10.1007/978-3-030-13636-9_29
Autor:
Taeyeong Ko, Marcelo Rocha Cruz, Jonathan F. Anker, Kyoungmin Lee, Wooyoung M. Choi, Sangmin Chang, Wade T. Iams, Young Kwang Chae, Sarita Agte
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-8 (2018)
Scientific Reports
Scientific Reports
Epithelial-mesenchymal transition (EMT) is able to drive metastasis during progression of multiple cancer types, including non-small cell lung cancer (NSCLC). As resistance to immunotherapy has been associated with EMT and immune exclusion in melanom
Autor:
Sarita Agte, Maria Matsangou, Jonathan F. Anker, Francis J. Giles, Young Kwang Chae, Andrew M. Davis, Wade T. Iams, Marcelo Rocha Cruz, William Bae, Wooyoung M. Choi
Publikováno v:
Scientific Reports
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Scientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
Immunotherapy is emerging as a promising option for lung cancer treatment. Various endothelial adhesion molecules, such as integrin and selectin, as well as various cellular barrier molecules such as desmosome and tight junctions, regulate T-cell inf
Publikováno v:
Breast Cancer Research and Treatment. 151:481-489
Bevacizumab may improve outcomes of patients with breast cancer, but the absence of an established biomarker hampers patient selection and researchers´ ability to demonstrate a clear survival benefit. Its putative target, circulating VEGF-A, emerged